Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed at $7.33 up 2.09% from its previous closing price of $7.18. In other words, the price has increased by $2.09 from its previous closing price. On the day, 0.89 million shares were traded. DNA stock price reached its highest trading level at $7.45 during the session, while it also had its lowest trading level at $7.03.
Ratios:
For a deeper understanding of Ginkgo Bioworks Holdings Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.71 and its Current Ratio is at 4.71. In the meantime, Its Debt-to-Equity ratio is 0.54 whereas as Long-Term Debt/Eq ratio is at 0.54.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 11 ’24 when Che Austin bought 99 shares for $7.08 per share.
Che Austin bought 99 shares of DNA for $773 on Oct 10 ’24. On Oct 09 ’24, another insider, Che Austin, who serves as the Officer of the company, bought 99 shares for $8.27 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 407367680 and an Enterprise Value of 102826552. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.09 while its Price-to-Book (P/B) ratio in mrq is 0.43. Its current Enterprise Value per Revenue stands at 0.558 whereas that against EBITDA is -0.162.
Stock Price History:
Over the past 52 weeks, DNA has reached a high of $75.20, while it has fallen to a 52-week low of $5.26. The 50-Day Moving Average of the stock is -10.27%, while the 200-Day Moving Average is calculated to be -75.40%.
Shares Statistics:
For the past three months, DNA has traded an average of 1.49M shares per day and 846310 over the past ten days. A total of 38.13M shares are outstanding, with a floating share count of 35.44M. Insiders hold about 32.59% of the company’s shares, while institutions hold 43.41% stake in the company. Shares short for DNA as of 1727654400 were 8187416 with a Short Ratio of 5.49, compared to 1724976000 on 7148536. Therefore, it implies a Short% of Shares Outstanding of 8187416 and a Short% of Float of 26.25.
